Clinical Research
Filter News
Found 104,154 articles
-
Maria Fardis, chief executive officer of Iovance Biotherapeutics, sees tumor infiltrating lymphocyte (TIL) therapies as the best immunotherapy option to treat solid cancers.
-
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
-
Study: Americans Unsure Whether Their Health Insurance Extends Outside The US
8/17/2018
n alarming number of Americans are unclear whether their health insurance works outside the US, according to a new survey from InsureMyTrip.
-
Market Set to Expand as Medical Use of Cannabis is Expected to Grow Globally
8/17/2018
According to the data published by Energias Market Research, the global medical cannabis market is projected to grow from USD 8.28 Billion in 2017 to USD 28.07 Billion in 2024 and at a CAGR of 19.1% from 2018 to 2024.
-
Dry Age-Related Macular Degeneration | A Drug Pipeline Analysis Report 2018 | Technavio
8/17/2018
Technavio has announced their latest pipeline analysis report on the drug pipeline for dry age-related macular degeneration.
-
ALS is a progressive neurodegenerative disease that affects neurons in the brain and the spinal cord. The disease is usually fatal within two to five years of diagnosis. While there is no cure for the disease, multiple companies are working on treatments hoping to be the first to provide a viable...
-
From Menopausal Nuns to Israeli Biotech: Israel’s BTG Developed First Genetically Modified Hormon...
8/16/2018
It’s been a while since FSH was manufactured using the urine of menopausal nuns. But now, an Israeli company, Bio-Technology General (BTG), owned by Italian company Ferring Pharmaceuticals, has developed a genetically-engineered version of FSH that can be personalized to improve the odds of a pat... -
Health Officials Remove Special NIH Oversite Rules Governing Gene Therapy Experiments: Report
8/16/2018
As gene therapies have become reality, the U.S. government is removing some special regulations that had been set up long ago over concerns of exotic safety risks. -
Biohaven Pharma, headquartered in New Haven, Conn., announced positive data from a proof-of-concept trial for its BHV-0223 in social anxiety and public speaking anxiety disorders.
-
BioNTech Inks $425 Million Collaboration Deal with Pfizer to Develop mRNA-based Flu Vaccines
8/16/2018
BioNTech, headquartered in Mainz, Germany, and Pfizer, based in New York City, signed a multi-year research-and-development deal to develop mRNA-based flu vaccines. -
Buck Institute, Insilico Med and Juvenescence Found Napa Therapeutics to Focus on Age-Related Dis...
8/16/2018
Yet another company is launched to focus on longevity and diseases of aging. The Buck Institute for Research on Aging, Insilico Medicine, an artificial intelligence (AI) company with offices and resources in the U.S., Belgium, Russia, the UK, Taiwan and Korea, and Juvenescence, also a human longe... -
Microbial Activity in the Mouth May Differentiate Children with Autism Spectrum Disorder
8/16/2018
New research suggests that shifts in the bacteria within a child’s mouth could provide objective biomarkers for identifying autism spectrum disorder.
-
New Research Reveals Dangers of Smoking Selfies on Social Media
8/16/2018
Big Tobacco gets a stream of free advertising from people on social media who post "smoking selfies," images that may help tobacco companies recruit more young smokers.
-
LACOG fights cancer with real-world data
8/16/2018
Only one in five low- and middle-income countries has the data necessary to drive cancer policy.
-
Eureka Therapeutics Announces Publication of Armored T-Cell Proof-of-Concept Study in Nature Biotechnology
8/16/2018
This approach was developed in collaboration with Renier J. Brentjens, M.D., Ph.D., Director of the Cellular Therapeutics Center at Memorial Sloan Kettering Cancer Center
-
NetworkNewsWire Announces Publication on Viable and Effective Alternatives for Nicotine Delivery
8/16/2018
NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP), a client of NNW focused on developing and out-licensing its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids and nicotine.
-
Plausible Link Between Epidural Drug and Fentanyl Addiction Published in Medical Hypotheses
8/16/2018
Researchers from the Healthy Children Project, Inc., a non-profit research and educational institution dedicated to improving child health outcomes, set out to investigate whether there might be a possible link between the exposure of the fetus to fentanyl - the most commonly prescribed opioid included in epidurals - during labor and later addiction of young adults to the opioid.
-
Reaching New Depths with the Immersive Power of Virtual Reality, Children's Charity Seeks to Ease the Stress and Pain of Critically Ill Pediatric Patients
8/16/2018
The Believe In Tomorrow Children's Foundation is restarting a 12-year-old research project exploring the effects of virtual reality technology on pediatric pain and stress management.
-
Elysium Health™ Announces Exclusive License for Use of Nicotinamide Riboside for the Slowing of Aging and Prevention of Age-Related Diseases from Mayo Clinic and Harvard
8/16/2018
Elysium Health, Inc.™ has entered into an exclusive license agreement with Mayo Clinic and Harvard University.
-
Potential mates drawn to smiles over bank account size finds Delta Dental survey
8/16/2018
But poor oral hygiene can cause a relationship hiatus